New oncolytic virus shows improved effectiveness in preclinical testing

Link to article at PubMed

A new fourth-generation oncolytic virus designed to both kill cancer cells and inhibit blood-vessel growth has shown greater effectiveness than earlier versions when tested in animal models. The virus is being developed as a treatment for glioblastoma, the most common and deadly form of brain cancer. The new virus improved survival of mice with transplanted human glioblastoma tumors by 50 percent in a majority of cases compared with the previous-generation oncolytic virus.

Leave a Reply

Your email address will not be published.